• Fang Liu, Udaya S Tantry, and Paul A Gurbel.
• Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory , 2401 W. Belvedere Ave, Baltimore, MD 21215 , USA +1 410 601 9600 ; +1 410 601 9601 ; pgurbel@lifebridgehealth.org.
• Expert Opin Pharmacother. 2015 Jun 1; 16 (8): 1149-65.

IntroductionIschemic stroke (IS) is a major cause of death and disability worldwide. The P2Y12 receptor plays a critical role in the formation of a stable thrombus leading to ischemic complications. Therefore, P2Y12 receptor inhibitors constitute a major antiplatelet strategy in the secondary prevention of IS.Areas CoveredWe searched articles about P2Y12 receptor inhibitors and stroke in PubMed published until December 2014. This is a comprehensive review of the role of P2Y12 receptor inhibitors alone and in combination with aspirin in the secondary prevention of noncardioembolic stroke.Expert OpinionThe potential benefit of more potent antiplatelet therapy for secondary stroke prevention must be weighed against the risk of bleeding in patients with IS. Short-term (≤ 3 months) dual antiplatelet therapy with clopidogrel and aspirin that is initiated early after IS or transient ischemic attack due to large artery atherosclerosis appears most efficient.

31 keywords...

hide…